Main Points:
– Celonic has integrated Merck’s Breez™ micro-bioreactor platform into its process development operations.
– This integration aims to enhance Celonic’s abilities in monoclonal antibody (mAb) development and manufacturing.
– The Breez platform is expected to enable highly efficient and scalable perfusion-based bioprocessing for Celonic.
Author’s Take:
Celonic has taken a significant step by incorporating Merck’s Breez micro-bioreactor platform into its operations, strengthening its position in mAb development and manufacturing. This integration showcases Celonic’s commitment to adopting advanced technologies to drive efficiency and scalability in bioprocessing, ultimately benefitting its overall operations.
Click here for the original article.